This document discusses HECOLCAP, a new product being developed by B2S to treat bone infections. HECOLCAP aims to enable sustained local delivery of antibiotics while also actively promoting bone regeneration in a single surgery, improving on current treatment which requires multiple surgeries and weeks of intravenous antibiotics. It has the potential to more effectively eradicate infections, reduce treatment time, and lower healthcare costs. An estimated 800,000 cases of bone infection in the US and Europe each year could benefit from HECOLCAP. The company is seeking €2.7 million in funding to complete product development and clinical studies.